News
WUXIF
22.70
NaN%
--
Weekly Report: what happened at WUXIF last week (0907-0911)?
Weekly Report · 2d ago
Weekly Report: what happened at WUXIF last week (0831-0904)?
Weekly Report · 09/07 10:32
Weekly Report: what happened at WUXIF last week (0824-0828)?
Weekly Report · 08/31 10:40
WuXi AppTec announces RMB 1.51B interim cash dividend for 2026
Seeking Alpha · 08/31 06:36
Weekly Report: what happened at WUXIF last week (0817-0821)?
Weekly Report · 08/24 10:41
Weekly Report: what happened at WUXIF last week (0810-0814)?
Weekly Report · 08/17 10:42
Weekly Report: what happened at WUXIF last week (0803-0807)?
Weekly Report · 08/10 10:36
Ariel International (DM/EM) Q2 2026 Portfolio Activity
Seeking Alpha · 08/07 10:11
Weekly Report: what happened at WUXIF last week (0727-0731)?
Weekly Report · 08/03 10:36
Weekly Report: what happened at WUXIF last week (0720-0724)?
Weekly Report · 07/27 10:41
Weekly Report: what happened at WUXIF last week (0713-0717)?
Weekly Report · 07/20 10:36
Weekly Report: what happened at WUXIF last week (0706-0710)?
Weekly Report · 07/13 10:39
ClearBridge International Growth Strategy: Adds ABB, BUD; exits SAP, Wuxi AppTec in Q2
Seeking Alpha · 07/10 16:26
Weekly Report: what happened at WUXIF last week (0629-0703)?
Weekly Report · 07/06 10:44
Weekly Report: what happened at WUXIF last week (0622-0626)?
Weekly Report · 06/29 10:37
Alibaba sues U.S. over Pentagon blacklist designation
Seeking Alpha · 06/23 19:30
Weekly Report: what happened at WUXIF last week (0615-0619)?
Weekly Report · 06/22 10:49
Baron Emerging Markets Fund adds VIST, JPSWY; exits MELI, XPEV among Q1 moves
Seeking Alpha · 06/09 14:19
Baron Emerging Markets Fund Q1 2026 Portfolio Activity
Seeking Alpha · 06/05 10:37
WuXi AppTec gives Q1 numbers
Seeking Alpha · 04/27 09:52
More
Webull provides a variety of real-time WUXIF stock news. You can receive the latest news about Wuxi Apptec through multiple platforms. This information may help you make smarter investment decisions.
About WUXIF
WuXi AppTec Co Ltd is a China-based company principally engaged in the business of new drug research and development and manufacturing services. The Company conducts its business through six segments. The WuXi Chemistry Segment is primarily engaged in providing new drug research, development and manufacturing services. The WuXi Testing Segment is primarily engaged in providing pharmaceuticals, medical devices, and in vitro diagnostic reagents services. The WuXi Biology Segment is primarily engaged in providing drug discovery and research services. The WuXi ATU Segment is primarily engaged in providing customers with integrated medical product process development, manufacturing and testing services. The WuXi DDSU Segment is primarily engaged in providing customers with integrated new drug research and development services. The Other Segment is primarily engaged in administrative services, sales of raw materials and sales of waste materials.